{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-03-18",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "East Brunswick",
      "state": "NJ",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "77427",
      "recalling_firm": "Lucid Pharma LLC",
      "address_1": "2 Tower Center Blvd",
      "address_2": "Suite 1101B",
      "postal_code": "08816-1100",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "Nationwide in the USA",
      "recall_number": "D-0921-2017",
      "product_description": "Venlafaxine Hydrochloride Extended-Release Capsules USP, 75 mg, packaged in a) 30-count bottles (NDC 52343-132-30) and b) 90-count bottles (NDC 52343-132-90), Rx only, Distributed by: Lucid Pharma LLC, 2 Tower Center Blvd, Suite-1101-B, East Brunswick, NJ 08816 USA.",
      "product_quantity": "a) 44168 bottles; b) 24960 bottles",
      "reason_for_recall": "Failed Tablet/Capsules Specifications: pharmacists complaints for bottles containing melted capsules.",
      "recall_initiation_date": "20170601",
      "center_classification_date": "20170616",
      "termination_date": "20190925",
      "report_date": "20170628",
      "code_info": "Lot #: a) V17516045-A, Exp  08/18; b) V17516047-A 09/18",
      "more_code_info": ""
    }
  ]
}